Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bone marrow-derived mesenchymal stem cells (University Hospital Tuebingen)
- Development stage
- Unknown
- Lead developer
- University Hospital Tuebingen
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells (MSCs), developed by the University Hospital Tuebingen. It is specifically being evaluated for the treatment of Acute Respiratory Distress Syndrome (ARDS) in patients suffering from severe COVID-19. MSCs are multipotent stromal cells characterized by their significant immunomodulatory and anti-inflammatory properties. The therapy aims to mitigate the hyper-inflammatory state and immune dysregulation, often termed a 'cytokine storm,' that leads to lung injury in SARS-CoV-2 infections. By secreting various paracrine factors, these cells promote the resolution of inflammation and support the repair of damaged alveolar tissue.
- Other names
- allogeneic bone marrow-derived human mesenchymal stem cellsallogeneic bone marrow-derived human mesenchymal stromal cellsMSCsmesenchymal stem cells-University Hospital Tuebingen-ARDS-COVID-19
Beyond the preview
Go deeper on bone marrow-derived mesenchymal stem cells (University Hospital Tuebingen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bone marrow-derived mesenchymal stem cells (University Hospital Tuebingen).